Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Yuichi Saito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Chiba University Graduate School of Medicine Chiba Japan. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Heart-Assist Devices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
In patients with cardiogenic shock (CS), a percutaneous microaxial ventricular assist device (Impella, Abiomed, Danvers, MA) is a choice for temporary mechanical circulatory support. Given the high morbidity and mortality in this patient population, early risk stratification is relevant when making treatment decisions.
Methods
Using nationwide registry data between February 2020 and December 2022 in Japan, we included a total of 4122 patients with cardiogenic shock treated with the Impella devices. Using logistic regression analysis, we incorporated patient characteristics and biomarkers to develop a risk‐stratifying model for in‐hospital mortality. The model was also tested if applicable to composite outcomes of in‐hospital death and major complications.
Results
Of the 4122 patients with cardiogenic shock, the Impella was indicated for acute myocardial infarction in 2575 (62.5%). Multivariable analysis identified 4 patient characteristics (age, body mass index, out‐of‐hospital cardiac arrest, and blood pressure) and 6 biomarkers (lactate, lactate dehydrogenase, creatinine, total bilirubin, albumin, and creatinine kinase) with cutoff values as factors significantly associated with in‐hospital mortality. We developed a risk‐stratifying model using the 10 variables, which was predictive of in‐hospital death (area under the curve, 0.711; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine Chiba University Graduate School of Medicine Chiba Japan.
- Biostatistics Section, Clinical Research Center Chiba University Hospital Chiba Japan.
- Department of Biostatistics, Graduate School of Medicine Saitama Medical University Saitama Japan.
- Department of Cardiovascular Surgery Dokkyo Medical University Saitama Medical Center Koshigaya Japan.
- Department of Cardiovascular Surgery Chiba University Graduate School of Medicine Chiba Japan.
ORCID-Profile: Yuichi Saito, Kazuya Tateishi
Zitieren
APA
Saito, Y., Shiko, Y., Tateishi, K., Toda, K., Matsumiya, G., Kobayashi, Y., & J‐PVAD Registry Study Investigators (2025). Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040487
Vancouver
Saito Y, Shiko Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y, et al. Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040487
BibTeX
@article{Saito2025,
author = {Saito, Yuichi and Shiko, Yuki and Tateishi, Kazuya and Toda, Koichi and Matsumiya, Goro and Kobayashi, Yoshio and J‐PVAD Registry Study Investigators, J‐PVAD Registry Study Investigators},
title = {Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040487}
}
EUVIMED